The short version of lyophilization fits in a sentence. The long version — which is the one that helps — is below.
Reviewed 2026-07-08. Anything still debated is marked as such rather than presented as settled.
Most published work on BPC-157 consists of preclinical studies, including rodent models of tissue injury, gastrointestinal lesions, and vascular or tendon damage, together with in vitro cell assays. Reviews frequently note that the mechanisms proposed in these papers remain incompletely characterised and that findings have not been confirmed in large randomised human trials. The compound is widely sold as a research chemical rather than a licensed medicine, and labels commonly carry a statement that it is not for human use. Whether any of the reported animal effects translate to humans is an open question rather than an established result.
Terminology in the literature is not fully standardised. Papers and product listings use BPC-157, BPC 157, and the longer phrase stable gastric pentadecapeptide BPC 157 interchangeably, and synonyms such as bepecin or PL 14736 appear in older or company-linked publications. Purity claims and reported masses can also differ between sources because peptide preparations may include counterions, residual solvents, or bound water. This variability complicates direct comparison of results across studies and makes the exact identity and grade of a given sample worth verifying. Discussions of the compound should therefore specify the source, salt form, and stated purity where those are known.
Confirmation of identity and purity relies on standard peptide analysis techniques. Reverse-phase high-performance liquid chromatography separates the peptide from related impurities and serves as the most common purity assay. Mass spectrometry, often coupled to that chromatography step, provides an accurate molecular mass that can be matched against the expected value. Amino acid analysis or sequencing can be added for further confirmation. Because short peptides can be produced by different synthetic routes, laboratories usually report both a chromatographic purity percentage and a mass confirmation rather than a single figure.
BPC-157 is commonly supplied as a lyophilized powder, a freeze-dried solid that is reconstituted before use in laboratory work. As a short peptide, it dissolves readily in water and in aqueous buffer solutions, and stock solutions are typically prepared in water or a mild buffer. The chain contains several proline and acidic residues, which influence how it behaves in solution. Because the solid can take up moisture, weighing and handling are usually performed under low-humidity conditions. Its solubility class is described as freely soluble in water rather than requiring an organic solvent.
Dry powder is generally stored at low temperature, with minus twenty degrees Celsius or colder advised for extended retention. Reconstituted solutions are less stable than the solid form and are normally kept cold and shielded from repeated freeze-thaw cycles. Light exposure is avoided because some peptides degrade under ultraviolet radiation. The exact rate of degradation depends on concentration, pH, and the presence of salts, so a single shelf life does not apply to every preparation. Reported stability figures should be read as indicative of typical handling rather than as universal constants.
| Property | Value | Notes |
|---|---|---|
| Molecular formula | C62H98N16O22 | Computed for the free peptide |
| Monoisotopic mass | Approximately 1419 Da | Reported values shift with counterion and hydration |
| Residue count | 15 amino acids | Sequence Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val |
| Origin | Fragment of human gastric juice protein | First described in early 1990s research reports |
| Common synonyms | BPC 157; PL 14736; bepecin | Naming varies across papers and catalogues |
The molecule carries 15 residues, a molar mass near 1419.5 g/mol, and the formula C62H98N16O22. Its structure features a proline-rich central region, a pair of adjacent aspartic acid residues, and no cysteine. The absence of cysteine means no disulfide bonds can form, which simplifies refolding and reconstitution. Suppliers usually ship the material as a freeze-dried powder that appears white to off-white. It dissolves readily in water and in saline solutions.
Published storage guidance follows general peptide practice rather than product-specific studies. The dry powder is typically kept at minus 20 degrees Celsius, away from light and moisture. Once reconstituted, solutions are generally refrigerated and used over days to weeks, because the aqueous environment slowly promotes hydrolysis and oxidation. Long-term data on degradation rates or breakdown products are sparse. Stated shelf lives from different producers vary widely, reflecting the absence of a shared reference standard.
Lyophilized peptide powder is generally stored at minus twenty degrees Celsius or lower and kept away from light and moisture. Under these conditions degradation is slow, and sealed vials remain stable for extended periods. Once dissolved, the material is less stable, particularly in aqueous buffers near neutral pH, where hydrolysis and oxidation proceed faster. Solutions are usually kept cold and used within days to weeks. Repeated freeze-thaw cycles are avoided because they encourage aggregation.
Identity and purity are established using reversed-phase high-performance liquid chromatography, which separates the peptide from related impurities and yields a percentage purity. Mass spectrometry, typically with electrospray ionization, confirms the molecular mass against the expected value. Amino acid analysis or peptide mapping provides additional sequence confirmation. These methods are complementary, since chromatography measures how much material is present while mass spectrometry verifies what that material is. A certificate of analysis normally reports both.
=== Overbilling the government === In 1992, the company was one of the first to be prosecuted as part of Operation Labscam, a nationwide crackdown on fraud in the healthcare system initiated by the U.S. Attorney's Office in San Diego, California. The company and others were accused of routinely submitting false claims to Medicare and Medicaid for unnecessary tests on blood samples that physicians had never ordered. In addition, charges for the tests billed to the government were significantly higher than what the company charged private insurers. That year, the company agreed to pay $111 million to settle claims. In November 1996, the company agreed to pay a total of $182 million as a result of the investigation. In February 2023, the company paid $19 million to resolve allegations that it violated the False Claims Act of 1863 by its submission of false claims to Medicare.
== Veterinary use == Buprenorphine is commonly used as a long-lasting post-operative analgesic in small animal veterinary practice. Buprenorphine can be administered via subcutaneous, transdermal, intravenous, or intramuscular routes. Buprenorphine provides analgesia for 6–8 hours in dogs and 4–8 hours in cats when administered as an intramuscular or intravenous injection. Buprenorphine as a partial agonist of the mu-receptor has less adverse effects than full agonists. A transdermal application can provide analgesia for up to 4 days in cats. The oral-transmucosal route has been investigated due to the potential for client administration but variability in bio-availability and other issues limit this usage. When used in combination with local anaesthetics or a non-steroidal anti-inflammatory drug buprenorphine provides good analgesia for ovariohysterectomies and orchidectomies. In horses buprenorphine can be used for castration and dental extraction; however, buprenorphine is not commonly used in horses as a post-operative analgesic due to potential for adverse gastrointestinal effects and locomotive stimulation. Buprenorphine is commonly given alongside acepromazine or a2 adrenergic receptor agonists
=== LS-SCLC === In cases of LS-SCLC, combination chemotherapy is administered together with concurrent chest radiotherapy. Chest radiotherapy has been shown to improve survival in LS-SCLC. Because SCLC usually metastasizes widely very early on in the natural history of the tumor, and because nearly all cases respond dramatically to chemotherapy and/or radiotherapy, there has been little role for surgery in this disease since the 1970s. However, in cases of small, asymptomatic, node-negative SCLC's ("very limited stage"), surgical excision may improve survival when used prior to chemotherapy.
[H3SO4]+[HSO4]− = 2.7 × 10−4 The corresponding equilibrium constant for water, Kw is 10−14, a factor of 1010 (10 billion) smaller. In spite of the viscosity of the acid, the effective molar conductivities of the H3SO+4 and HSO−4 ions are high due to an intramolecular proton-switch mechanism (analogous to the Grotthuss mechanism in water), making sulfuric acid a good conductor of electricity.
=== Bellagio Center === The foundation also owns and operates the Bellagio Center in Bellagio, Italy. The center has several buildings, spread across a 50-acre (200,000 m2) property, on the peninsula between lakes Como and Lecco in Northern Italy. The center is sometimes referred to as the "Villa Serbelloni", the property bequeathed to the foundation in 1959 under the presidency of Dean Rusk (who was later to become U.S. President Kennedy's secretary of state).
Sources: en.wikipedia.org
Relaxin/insulin-like family peptide receptor 2, also known as RXFP2, is a human G-protein coupled receptor. The receptors for glycoprotein hormones such as follicle-stimulating hormone (FSH; see MIM 136530) and thyroid-stimulating hormone (TSH; see MIM 188540) are G protein-coupled, 7-transmembrane receptors (GPCRs) with large N-terminal extracellular domains. Leucine-rich repeat (LRR)-containing GPCRs (LGRs) form a subgroup of the GPCR superfamily. [supplied by OMIM].
== Balanced salt solutions == Alsever's solution Earle's balanced salt solution (EBSS) Gey's balanced salt solution (GBSS) Hanks' balanced salt solution (HBSS) (Dulbecco's) Phosphate buffered saline (PBS) Puck's balanced salt solution Ringer's balanced salt solution (RBSS) Simm's balanced salt solution (SBSS) TRIS-buffered saline (TBS) Tyrode's balanced salt solution (TBSS)
== Early life == Geneviève Meurgues was born on 4 February 1931 in Paris, into a family originally from Saint-Germain-de-Modéon. She had sister and brother, Christiane and Bernard. Until 1962, she worked in a medical analysis laboratory while completing her education in chemistry and biochemistry at the Conservatoire national des arts et métiers. She graduated as a chemical engineer in 1967, writing her thesis on the nucleic acids of the fungus Aspergillus niger.
While the largest part of uranium-236 has been produced by neutron capture in nuclear power reactors, that part is nearly all stored in nuclear reactors and waste repositories and has not been released to the environment. The most significant environmental contribution is the 238U(n,3n)236U reaction by fast neutrons in thermonuclear weapons. The nuclear testing of the 1940s, 1950s, and 1960s (atmospheric testing ended 1963) has raised the environmental abundance levels significantly above the expected natural levels.
Sources: en.wikipedia.org
BPC-157 is a synthetic fifteen-amino-acid peptide whose sequence corresponds to a fragment of a protein found in human gastric juice. It is studied mainly in preclinical research and is not an approved pharmaceutical product in major markets. Materials sold for laboratory use are typically labelled as research chemicals.
No medicines regulator in the United States or the European Union has approved BPC-157 as a therapeutic product. Presenting it as a drug or as a dietary supplement ingredient would generally not match its regulatory status. Availability as a research chemical does not imply clinical approval.
Published reports rest largely on animal models and cell culture rather than controlled human trials. Review articles describe the proposed mechanisms as incompletely understood. Conclusions about effects in humans therefore remain tentative.
The lyophilized powder is normally kept at minus twenty degrees Celsius or colder. Solutions are held at refrigerator temperature or below and protected from light. Repeated freezing and thawing is avoided because it can promote aggregation or loss of activity.